KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $12.4 million.

  • Rigel Pharmaceuticals' Share-based Compensation rose 27.19% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year decrease of 1.54%. This contributed to the annual value of $12.4 million for FY2024, which is 40.73% up from last year.
  • Rigel Pharmaceuticals' Share-based Compensation amounted to $12.4 million in FY2024, which was up 40.73% from $8.8 million recorded in FY2023.
  • Rigel Pharmaceuticals' Share-based Compensation's 5-year high stood at $12.4 million during FY2024, with a 5-year trough of $7.3 million in FY2020.
  • Moreover, its 3-year median value for Share-based Compensation was $12.4 million (2022), whereas its average is $11.2 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first fell by 28.90% in 2023, then surged by 40.73% in 2024.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' Share-based Compensation stood at $7.3 million in 2020, then increased by 30.00% to $9.5 million in 2021, then soared by 30.56% to $12.4 million in 2022, then fell by 28.90% to $8.8 million in 2023, then surged by 40.73% to $12.4 million in 2024.